Compare SKY & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | ADPT |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 1994 | 2019 |
| Metric | SKY | ADPT |
|---|---|---|
| Price | $90.36 | $25.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $98.50 | $17.78 |
| AVG Volume (30 Days) | 697.5K | ★ 2.3M |
| Earning Date | 05-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.02 | ★ 63.89 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $2,663,639,000.00 | $276,976,000.00 |
| Revenue This Year | $7.79 | $3.98 |
| Revenue Next Year | $3.10 | $22.72 |
| P/E Ratio | $101.16 | ★ N/A |
| Revenue Growth | 7.26 | ★ 54.77 |
| 52 Week Low | $63.69 | $12.00 |
| 52 Week High | $99.17 | $26.87 |
| Indicator | SKY | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 59.47 |
| Support Level | $89.31 | $23.92 |
| Resistance Level | $98.08 | $26.16 |
| Average True Range (ATR) | 2.33 | 1.01 |
| MACD | -0.55 | -0.05 |
| Stochastic Oscillator | 18.20 | 62.71 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.